US Stock Futures Edge Higher Ahead Of Economic Data

Loading...
Loading...
Pre-open movers
US stock futures traded higher in early pre-market trade. The Empire State manufacturing index for May will be released at 8:30 a.m. ET. Data on industrial production for April will be released at 9:15 a.m. ET, while the University of Michigan's consumer sentiment index for May will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average surged 19.50 points to 18,221.50, while the Standard & Poor's 500 index futures rose 2.45 points to 2,119.95. Futures for the Nasdaq 100 index gained 12.15 points to 4,502.40.
A Peek Into Global Markets
European markets were higher today, with the Spanish Ibex Index rising 0.09 percent, STOXX Europe 600 Index gaining 0.52 percent and German DAX 30 index gaining 0.35 percent. French CAC 40 Index rose 0.48 percent and London's FTSE 100 Index rose 0.44 percent. In Asian markets, Japan's Nikkei Stock Average rose 0.83 percent, China's Shanghai Composite Index fell 1.59 percent, Hong Kong's Hang Seng Index gained 1.96 percent and India's BSE Sensex climbed 0.43 percent.
Broker Recommendation
Analysts at Goldman Sachs upgraded
United Parcel Service, Inc. UPS
from Buy to Neutral and raised the price target from $101.00 to $119.00. UPS shares rose 1.24 percent to $101.92 in pre-market trading.
Breaking news
  • Dillard's, Inc. DDS reported weaker-than-expected results for the first quarter on Thursday. To read the full news, click here.
  • Ocular Therapeutix, Inc. OCUL today announced financial results for the first quarter ended March 31, 2015 and provided an update on its clinical and preclinical programs for its proprietary hydrogel platform technology. To read the full news, click here.
  • Nordstrom, Inc. JWN reported weaker-than-expected earnings for the first quarter on Thursday, but the company's sales exceeded analysts' estimates. To read the full news, click here.
  • Amgen AMGN today announced the first results from its global Phase 2, double-blind, placebo-controlled study evaluating the efficacy and safety of AMG 334 for the prevention of episodic migraine. The study met its primary endpoint of reducing monthly mean migraine days compared with placebo. To read the full news, click here.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsGoldman SachsUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...